Press Releases

Press Releases

November 29, 2018
Presentations focus on the benefits of treatment with TEGSEDI™ (inotersen) and results show continued efficacy with long-term exposure in the NEURO-TTR open-label extension study BOSTON , Nov. 29, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis
November 12, 2018
Approximately 98% of patients receiving highest dose achieved reductions in Lp(a) levels below the established threshold of risk for CVD events Favorable safety and tolerability profile observed in largest study ever conducted in patients with cardiovascular disease and elevated Lp(a) BOSTON and
November 8, 2018
Results to be presented show a significant reduction of Lp(a) levels, favorable safety and tolerability profile BOSTON and CARLSBAD, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals,
November 6, 2018
BOSTON , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced that management will present a company overview at the
November 5, 2018
TEGSEDI TM (inotersen) Approved in United States , European Union & Canada          $320 million to fund the company through key milestones Conference Call Webcast Monday, November 5 , 4:30 p.m. ET at www.akceatx.com BOSTON , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc.
November 2, 2018
Community focuses on elevating awareness of the burden of FCS and impact on daily living BOSTON , Nov. 02, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics , Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , today recognizes the inaugural Familial Chylomicronemia Syndrome (FCS) Awareness
October 22, 2018
Webcast scheduled for Monday, November 5 th at 4:30 p.m. Eastern Time BOSTON , Oct. 22, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , announced today that it will host a live webcast on Monday, November 5 th at 4:30 p.m.
October 8, 2018
Dr. Damien McDevitt replaces Dr. Stanley Crooke on Akcea Board of Directors The change enhances focus on global approval and commercialization of TEGSEDI™ (inotersen) BOSTON , Oct. 08, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc.
October 5, 2018
Express Scripts’ Accredo® selected as specialty pharmacy for its expertise in providing timely access and support services for patients living with rare diseases BOSTON , Oct. 05, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc.
October 5, 2018
TEGSEDI provides powerful knockdown of TTR protein, delivering significant and sustained benefits in neuropathy and quality of life Hereditary Transthyretin (hATTR) Amyloidosis Infographic AKCEA CONNECT™ Infographic TEGSEDI™ (inotersen) Product Shot Ionis Pharmaceuticals Logo TEGSEDITM(inotersen)